R
Ruchi Tiwari
Researcher at Pranveer Singh Institute of Technology
Publications - 315
Citations - 15581
Ruchi Tiwari is an academic researcher from Pranveer Singh Institute of Technology. The author has contributed to research in topics: Medicine & Coronavirus. The author has an hindex of 50, co-authored 289 publications receiving 10401 citations. Previous affiliations of Ruchi Tiwari include Indian Council of Agricultural Research & Indian Institute of Technology Delhi.
Papers
More filters
Journal ArticleDOI
The kidney and COVID-19 patients - Important considerations.
Shailesh Kumar Patel,Rohit Singh,Jigyasa Rana,Ruchi Tiwari,Senthilkumar Natesan,Harapan Harapan,Kovy Arteaga-Livias,D. Katterine Bonilla-Aldana,Alfonso J. Rodriguez-Morales,Kuldeep Dhama +9 more
Journal ArticleDOI
Susceptibility of felids to coronaviruses.
Alfonso J. Rodriguez-Morales,Kuldeep Dhama,Khan Sharun,Ruchi Tiwari,D. Katterine Bonilla-Aldana +4 more
TL;DR: The pathological changes induced by the experimental inoculation of SARS-CoV in cats were similar to those induced by conventional inoculation, although without clinical signs.
Journal ArticleDOI
Dexamethasone: A boon for critically ill COVID-19 patients?
Shailesh Kumar Patel,G. Saikumar,Jigyasa Rana,Jaideep Dhama,Mohd Iqbal Yatoo,Ruchi Tiwari,Alfonso J. Rodriguez-Morales,Kuldeep Dhama +7 more
Journal ArticleDOI
Systematic Review on Anticancer Potential and other Health Beneficial Pharmacological Activities of Novel Medicinal Plant Morinda citrifolia (Noni)
Mani Saminathan,R. B. Rai,Kuldeep Dhama,Ruchi Tiwari,Sandip Chakrabort,Amarpal,G. J. Ranganath,Kandasamy Kannan +7 more
Journal ArticleDOI
Immunotherapies and immunomodulatory approaches in clinical trials - a mini review.
Mohd Iqbal Yatoo,Zeenat Hamid,Izhar Rather,Qurat Ul Ain Nazir,Riyaz Ahmed Bhat,Abrar Ul Haq,Suhail Nabi Magray,Zulfqar Haq,Ranjit Sah,Ruchi Tiwari,Senthilkumar Natesan,Muhammad Bilal,Harapan Harapan,Kuldeep Dhama +13 more
TL;DR: In this paper, the authors have highlighted the need to strengthen the field of developing effective immunotherapeutics and immunomodulators with a thrust of providing appropriate, affordable, convenient, and cost-effective prophylactic and treatment regimens to combat global COVID-19 crisis that has led to a state of medical emergency enforcing entire countries of the world to devote their research infrastructure and manpower in tackling this pandemic.